Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Pfizer (PFE) reported $17.56 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.2%. EPS of $0.66 for the same period compares to $0.63 a year ago.The reported revenue represents a surprise of +4.26% over the Zacks Consensus Estimate of $16.84 billion. With the consensus EPS estimate being $0.57, the EPS surprise was +16.81%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Oncology- Ibrance- United States: $686 million versus $665.8 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.8% change.Revenues- Specialty Care- Xeljanz- Total International: $131 million versus $112.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.Revenues- Oncology- Xtandi- United States: $592 million compared to the $622.1 million average estimate based on three analysts. The reported number represents a change of +4.8% year over year.Revenues- Specialty Care- Inflectra- United States: $157 million compared to the $150.8 million average estimate based on three analysts. The reported number represents a change of +145.3% year over year.Revenues- Oncology- Ibrance- Worldwide: $1.04 billion versus $1.03 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5% change.Revenues- Specialty Care- Xeljanz- Worldwide: $324 million versus the three-analyst average estimate of $335.3 million. The reported number represents a year-over-year change of -7.2%.Revenues- Specialty Care- Inflectra- Worldwide: $181 million versus the three-analyst average estimate of $173.25 million. The reported number represents a year-over-year change of +42.5%.Revenues- Oncology- Xtandi- Worldwide: $592 million versus $622.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.Revenues- Oncology- Inlyta- Worldwide: $235 million compared to the $188.27 million average estimate based on three analysts. The reported number represents a change of -2.9% year over year.Revenues- Specialty Care- Worldwide: $4.77 billion versus the three-analyst average estimate of $4.66 billion. The reported number represents a year-over-year change of +7.5%.Revenues- Primary Care- Worldwide: $7.94 billion versus $7.55 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.9% change.Revenues- Primary Care- Eliquis- Worldwide: $2.02 billion versus the three-analyst average estimate of $2.13 billion. The reported number represents a year-over-year change of +10.3%.View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned +5.9% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks